We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Roll on next week, potential transformational news fast approaching and hopefully Prof Chalmers is going to be very happy, but obviously not about tonights game...C'mon England!!! ;-)
The US funding and Boris's home pill Autumn target highlight SFX 01's incredible potential ...positive efficacy data could propel Evgen into the global spotlight and global investor focus. Gl :-)
Several companies, including Pfizer, Roche and AstraZeneca, are testing antivirals in pill form.
Until this week, the only medicines shown to boost survival were steroids given to patients sick enough to need extra oxygen and intensive care. But on Wednesday, U.K. researchers reported that one of the antibody combinations successfully reduced deaths in a large study of hospitalized COVID-19 patients.
.........
Ps and if anyone was wondering what UK researchers the article was referring....Gl.:-)
TOPLINE
Regeneron’s Covid-19 antibody therapy is capable of slashing death rates among hospitalized patients who do not have a natural immune response against the virus, according to preliminary findings from a U.K. study that could change how it is used in practice and revitalize interest in antiviral treatments to help those who have contracted the disease.
Regeneron’s therapy—an expensive intravenous antibody ****tail that neutralizes the virus—cut the risk of death by a fifth in hospitalized patients who had not mounted a natural antibody response of their own, according to data from the U.K.’s RECOVERY trial.
Lol Nolupus, just looked in here for the first time today to post the following, mentioned by amarreto on Adfvn, but already highlighted by you in your link, great find aand highly relevant to SFX-01's potential efficacy for Covid/Ards...positive data will be a game changer and could see SFX-01 as prime candidate for Boris's home pill autumn target, not to mention the mega bucks from across the pond. Gl ;-)
WASHINGTON (AP) — The United States is devoting $3.2 billion to advance development of antiviral pills for COVID-19 and other dangerous viruses that could turn into pandemics.
Dr. Anthony Fauci, the nation’s top infectious disease expert, announced the investment Thursday at a White House briefing as part of a new “antiviral program for pandemics” to develop drugs to address symptoms caused by potentially dangerous viruses like the coronavirus.
The pills for COVID-19, which would be used to minimize symptoms after infection, are in development and could begin arriving by year’s end, pending the completion of clinical trials. The funding will speed those clinical trials and provide additional support to private sector research, development and manufacturing.
Fauci said the new program would invest in “accelerating things that are already in progress” for COVID-19 but also would work to innovate new therapies for other viruses.
“There are few treatments that exist for many of the viruses that have pandemic potential," he said.
But he added, “vaccines clearly remain the centerpiece of our arsenal.”
The U.S. has approved one antiviral drug, remdesivir, against COVID-19 and allowed emergency use of three antibody combinations that help the immune system fight the virus. But all the drugs have to be infused at hospitals or medical clinics, and demand has been low due to these logistical hurdles.
The U.S. government has been trying to raise awareness of the treatments, connecting people who test positive for COVID-19 with information about nearby providers.
Health experts, including Fauci, have increasingly called for simpler pill-based drugs that patients could take themselves. Some drugmakers are testing such medications, but initial results aren’t expected for several more months.
The currently available drugs have mostly been shown to help patients avoid hospitalization or shorten their recovery time by several days.
Under President Donald Trump, the U.S. poured more than $19 billion into rapidly developing multiple vaccines. But less than half that amount went toward developing new treatments. That shortfall has become increasingly concerning as the vaccination campaign slows and experts emphasize the need to manage the disease in millions of Americans who may never get inoculated.
The biggest need is for a convenient pill that can help keep patients with early symptoms of COVID-19 from developing severe disease and needing hospitalization.